AT 04
Alternative Names: AT-04Latest Information Update: 28 Jun 2025
At a glance
- Originator Attralus
- Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Peptide fragments; Recombinant fusion proteins
- Mechanism of Action Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
- No development reported Amyloidosis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Amyloidosis in USA (Parenteral)
- 03 Apr 2023 Pharmacodynamics data from a preclinical studies in Neurodegenerative disorders released by Attralus
- 17 Nov 2022 Attralus in-licenses VNAR antibody-based brain shuttle TXP1 antibody technology from Ossianix